ERBB2 and breast carcinoma: Both clinical and preclinical studies show that treatment with trastuzumab alters immune infiltration (including myeloid populations) in HER2+ tumors [27–29]; however, to our knowledge, a detailed immune panel in HER2+ breast cancer identifying changes in myeloid populations to trastuzumab has not been conducted.